• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

The risk of in-transit melanoma metastasis depends on tumor biology and not the surgical approach to regional lymph nodes.

作者信息

Pawlik Timothy M, Ross Merrick I, Thompson John F, Eggermont Alexander M M, Gershenwald Jeffrey E

机构信息

Department of Surgical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA.

出版信息

J Clin Oncol. 2005 Jul 20;23(21):4588-90. doi: 10.1200/JCO.2005.12.245.

DOI:10.1200/JCO.2005.12.245
PMID:16034040
Abstract
摘要

相似文献

1
The risk of in-transit melanoma metastasis depends on tumor biology and not the surgical approach to regional lymph nodes.黑色素瘤术中转移的风险取决于肿瘤生物学特性，而非区域淋巴结的手术方式。
J Clin Oncol. 2005 Jul 20;23(21):4588-90. doi: 10.1200/JCO.2005.12.245.
2
[Sentinel lymph node biopsy and incidence of recurrence].[前哨淋巴结活检与复发率]
Hautarzt. 2006 Mar;57(3):182.
3
Selective lymphadenectomy in sentinel node-positive patients may increase the risk of local/in-transit recurrence in malignant melanoma.对前哨淋巴结阳性的患者进行选择性淋巴结清扫术可能会增加恶性黑色素瘤局部/区域转移复发的风险。
Eur J Surg Oncol. 2005 Mar;31(2):211-2. doi: 10.1016/j.ejso.2004.09.015.
4
The chances of a patient with melanoma developing in transit disease are doubled by undergoing sentinel lymph node biopsy (SLNB).黑色素瘤患者发生移行转移的几率会因接受前哨淋巴结活检（SLNB）而增加一倍。
Eur J Surg Oncol. 2005 Mar;31(2):210-1. doi: 10.1016/j.ejso.2004.10.009.
5
[Sentinel node diagnosis in malignant melanoma. Reflections on relapse after histologically negative sentinel node].[恶性黑色素瘤前哨淋巴结诊断。组织学检查前哨淋巴结阴性后的复发思考]
Ugeskr Laeger. 2003 Sep 22;165(39):3735-6.
6
[Risk factors for in-transit metastasis in patients with cutaneous melanoma].[皮肤黑色素瘤患者发生途中转移的危险因素]
Actas Dermosifiliogr. 2012 Apr;103(3):207-13. doi: 10.1016/j.ad.2011.06.002. Epub 2011 Sep 6.
7
Analysis of sentinel lymph nodes in melanoma: technique versus rationale.黑色素瘤前哨淋巴结的分析：技术与原理
Am J Surg Pathol. 2006 Mar;30(3):417-8; author reply 420-1. doi: 10.1097/01.pas.0000189177.62321.ml.
8
[Prognosis after sentinel node biopsy in malignant melanoma].[恶性黑色素瘤前哨淋巴结活检后的预后]
Ugeskr Laeger. 2006 Jun 19;168(25):2457-62.
9
Re: Selective lymphadenectomy in sentinel node-positive patients may increase the risk of local/in-transit recurrence in malignant melanoma, Thomas and Clark.关于：前哨淋巴结阳性患者的选择性淋巴结清扫术可能会增加恶性黑色素瘤局部/区域复发风险，托马斯和克拉克
Eur J Surg Oncol. 2005 Apr;31(3):323-4. doi: 10.1016/j.ejso.2004.11.010.
10
The evolution of the management of regional lymph nodes in melanoma.
J Surg Oncol. 2007 Sep 15;96(4):316-21. doi: 10.1002/jso.20867.

引用本文的文献

1
Management of In-transit Disease: Regional Therapies, Intralesional Therapies, and Systemic Therapy.转运中疾病的管理：局部治疗、病灶内治疗和全身治疗。
Surg Oncol Clin N Am. 2025 Jul;34(3):393-410. doi: 10.1016/j.soc.2024.11.004. Epub 2024 Dec 6.
2
Successful treatment of in-transit metastatic melanoma with combination intralesional T-VEC and topical imiquimod immunotherapy.联合瘤内 T-VEC 和外用咪喹莫特免疫疗法成功治疗转移性黑色素瘤。
J Immunother Cancer. 2024 Nov 19;12(11):e009581. doi: 10.1136/jitc-2024-009581.
3
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of melanoma, version 3.0.
癌症免疫治疗学会（SITC）临床实践指南：免疫治疗治疗黑色素瘤，第 3.0 版。
J Immunother Cancer. 2023 Oct;11(10). doi: 10.1136/jitc-2023-006947.
4
Oncolytic intralesional therapy for metastatic melanoma.瘤内溶瘤治疗转移性黑色素瘤。
Clin Exp Metastasis. 2024 Aug;41(4):457-460. doi: 10.1007/s10585-023-10228-4. Epub 2023 Aug 9.
5
Potential dual synergy between electrochemotherapy and sequence of immunotherapies in metastatic melanoma: A case report.转移性黑色素瘤中电化学疗法与免疫疗法顺序之间的潜在双重协同作用：一例报告。
Mol Clin Oncol. 2023 Jan 10;18(2):8. doi: 10.3892/mco.2023.2604. eCollection 2023 Feb.
6
Malignant melanoma with in-transit metastases refractory to programmed cell death-1 inhibitor successfully treated with local interferon-β injections: A case report.经程序性细胞死亡蛋白1抑制剂治疗无效的伴有皮肤转移的恶性黑色素瘤，采用局部注射干扰素-β成功治愈：一例报告
Mol Clin Oncol. 2021 Oct;15(4):212. doi: 10.3892/mco.2021.2374. Epub 2021 Aug 10.
7
In-transit metastatic cutaneous melanoma: current management and future directions.转移性皮肤黑色素瘤的术中转移：当前的治疗方法和未来的方向。
Clin Exp Metastasis. 2022 Feb;39(1):201-211. doi: 10.1007/s10585-021-10100-3. Epub 2021 May 17.
8
Contemporary Approaches to In-Transit Melanoma.当代转运期黑色素瘤处理方法。
J Oncol Pract. 2018 May;14(5):292-300. doi: 10.1200/JOP.18.00063.
9
Regional therapies for in-transit disease.区域内转移病灶的治疗方法。
Surg Oncol Clin N Am. 2015 Apr;24(2):309-22. doi: 10.1016/j.soc.2014.12.008. Epub 2015 Jan 30.
10
Long-lasting response to electrochemotherapy in melanoma patients with cutaneous metastasis.电化学疗法治疗皮肤转移性黑色素瘤患者的持久应答。
BMC Cancer. 2013 Dec 1;13:564. doi: 10.1186/1471-2407-13-564.